EQS-News: Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Running a 2,000 patient study, with average risk patients in the U.S., to read out by the end of 2025 (eAArly DETECT 2). With eAArly DETECT 2, the Company addresses FDA feedback and prepares for a new ...
Mainz Biomed reports FY24 EPS ($22.36) vs ($64.76) last year
Reports FY24 revenue $893,991 vs $895,479 last year. “We are proud of the accomplishments our team achieved in 2024, which was a transitional ...
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss ...
Mainz BioMed NV: Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
Average-Risk Patient Study Seeks to Confirm Mainz Biomed's Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report ...
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous ...